The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
 
Alice Bernard-Tessier
No Relationships to Disclose
 
Tapio Utriainen
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst); Orion (Inst)
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
(OPTIONAL) Uncompensated Relationships - Roche
 
Philippe Barthélémy
Honoraria - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; MSD; Pfizer
 
Nada Lallous
Research Funding - Aranda Pharma (Inst); Orion (Inst)
 
Martin Gleave
Stock and Other Ownership Interests - Sitka; Sustained Therapeutics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Roche; Sanofi; Tersera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Roche; Sanofi; Tersera
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427; Sitka - preclinical company focused on novel formulations of taxanes as intravesical agents for superficial bladder cancer; ST-CP; ST-POP
 
Tarja Ikonen
Employment - Orion
 
Reetta Riikonen
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Pasi Pohjanjousi
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Chris Garratt
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); ESSA (Inst); Janssen Oncology (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD